251,578 Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA increased its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 41.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 860,228 shares of the company’s stock after acquiring an additional 251,578 shares during the quarter. Pictet Asset Management Holding SA owned 1.10% of Kiniksa Pharmaceuticals International worth $64,182,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. AlphaCentric Advisors LLC bought a new position in Kiniksa Pharmaceuticals International during the third quarter worth $596,000. Commonwealth Equity Services LLC grew its holdings in Kiniksa Pharmaceuticals International by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after purchasing an additional 237 shares during the period. Chicago Partners Investment Group LLC bought a new stake in Kiniksa Pharmaceuticals International in the third quarter valued at $226,000. Ascent Group LLC increased its stake in Kiniksa Pharmaceuticals International by 16.0% in the third quarter. Ascent Group LLC now owns 3,796 shares of the company’s stock valued at $283,000 after purchasing an additional 523 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Kiniksa Pharmaceuticals International in the third quarter valued at $184,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on KNSA shares. Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Citigroup raised their target price on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Wedbush boosted their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a research report on Wednesday, October 28th. Finally, Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and a consensus price target of $100.57.

Kiniksa Pharmaceuticals International Stock Up 5.2%

Shares of KNSA opened at $98.76 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $37.02 and a 12-month high of $99.31. The business’s fifty day moving average is $80.87 and its 200 day moving average is $61.65. The stock has a market cap of $7.71 billion, a P/E ratio of 75.97 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. The business had revenue of $285.97 million during the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, insider John Paolini sold 77,587 shares of the firm’s stock in a transaction on Friday, October 30th. The shares were sold at an average price of $93.02, for a total value of $7,217,142.74. Following the transaction, the insider directly owned 69,922 shares of the company’s stock, valued at approximately $6,504,144.44. This trade represents a 52.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark Ragosa sold 36,783 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $92.16, for a total transaction of $3,389,921.28. Following the transaction, the chief financial officer owned 20,854 shares of the company’s stock, valued at $1,921,904.64. This represents a 63.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 831,022 shares of company stock valued at $77,475,599. 51.98% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally.

Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

The company also develops investigational therapies for inflammatory and immune-mediated conditions, including treatments that target pathways involved in immune-cell activity.